+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Japan Indapamide Market 2020-2026

  • PDF Icon


  • August 2020
  • Region: Japan
  • Orion Market Research Private Limited
  • ID: 5148148
Japan Indapamide Market Size, Share & Trends Analysis Report by product (1.25 mg and 2.5 mg), By Application (High Blood Pressure, Heart Failure, and Others), and Forecast 2020-2026.

Japan indapamide market is estimated to grow at a CAGR of around 1.7% during the forecast period. The growth is attributed to the rising number of hypertension and diabetes patients in the country. As per the IDF, in 2019, the total cases of diabetes in adults were 7.4 million, which accounted for nearly 7.9% of the total adult population in the country. The factors that are contributing to the increasing prevalence of diabetes include the presence of a significant obese population. As per the World Bank, between 1997 and 2016, in Japan, the prevalence of obesity, male (% of male population ages 18+) increased substantially from 1.6% to 4.8%. As per the National Health Service (NHS), individuals with hypertension were found to have a risk of more than 70% of developing type 2 diabetes. Therefore, it is expected that a significant number of diabetes patients may also have hypertension in the country which may increase the possibility of severe conditions, including heart failure and kidney diseases. This, in turn, will likely drive the demand for indapamide in the country.

Japan indapamide market is segmented on the basis of product and application. Based on the product, the market is bifurcated into 1.25 mg and 2.5 mg. Among these, the market for 1.25 mg medicine held a significant market share owing to the extensive application of the drug in treating high blood pressure or hypertension. Based on the application, the market is segmented into high blood pressure, heart failure, and others. The high blood pressure segment is projected to have a significant share in the market. Growing incidence of hypertension is contributing to market growth as indapamide drugs are significantly used to treat hypertension while reducing the risk of developing serious heart conditions.

The companies which are contributing to the growth of the Japan indapamide market include Glenmark Pharmaceuticals Ltd, Shandong Yinfeida Pharmaceutical Co., Ltd., Suzhou Lixin Pharmaceutical Co., Ltd., Merck KGaA, Sanofi S.A., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations to stay competitive in the market.

Research Methodology:

The market study of the Japan indapamide market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:
  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for indapamide market players, pharmaceutical companies, drug manufacturers, government organizations, regulatory bodies, and other market participants for the overall market and competitive analysis. The report provides an in-depth analysis on market size, products offered by the companies, and future market opportunities. The report will serve as a source for 360-degree analysis of the market delivering insights into the market for making better business decisions.

Market Segmentation:

1. Japan Indapamide Market Research and Analysis by Product
2. Japan Indapamide Market Research and Analysis by Application

The Report Covers:
  • Comprehensive research methodology of the Japan indapamide market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the Japan indapamide market.
  • Insights about market determinants which are stimulating the Japan indapamide market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Determinants
4.1. Motivators
4.2. Restraints/Challenges
4.3. Opportunities
5. Market Segmentation
5.1. Japan Indapamide Market by Product
5.1.1. 1.25 MG
5.1.2. 2.5 MG
5.2. Japan Indapamide Market by Application
5.2.1. High Blood Pressure
5.2.2. Heart Failure
5.2.3. Others
6. Company Profiles
6.1. ANI Pharmaceuticals, Inc.
6.2. Glenmark Pharmaceuticals Ltd.
6.3. Merck KGaA
6.4. Sandoz International GmbH
6.5. Sanofi S.A.
6.6. Shandong Yinfeida Pharmaceutical Co., Ltd.
6.7. Supra Chemicals
6.8. Suzhou Lixin Pharmaceutical Co., Ltd.
6.9. Taj Pharmaceuticals Ltd.
6.10. Torrent Pharmaceuticals Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • ANI Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Merck KGaA
  • Sandoz International GmbH
  • Sanofi S.A.
  • Shandong Yinfeida Pharmaceutical Co., Ltd.
  • Supra Chemicals
  • Suzhou Lixin Pharmaceutical Co., Ltd.
  • Taj Pharmaceuticals Ltd.
  • Torrent Pharmaceuticals Ltd.